Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Immunome ( (IMNM) ) is now available.
On May 8, 2025, Immunome‘s Board of Directors approved an amendment to increase the number of shares reserved under its 2024 Inducement Plan, aimed at attracting new employees. The company reported its first-quarter 2025 financial results, highlighting a net loss of $41.6 million and a cash position expected to fund operations into 2027. Immunome is progressing with its clinical trials, including the Phase 3 RINGSIDE trial for varegacestat and Phase 1 trials for IM-1021 and IM-3050, positioning itself as a leader in targeted cancer therapies.
The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.
Spark’s Take on IMNM Stock
According to Spark, TipRanks’ AI Analyst, IMNM is a Neutral.
Immunome’s stock score reflects its significant financial hurdles, including negative income and cash flows, which weigh heavily on its performance. Technically, the stock is showing bearish indicators, though some moderate signals suggest potential stabilization. The valuation is unattractive due to negative earnings and no dividend yield. Overall, the stock is facing challenges, with financial performance as the primary concern.
To see Spark’s full report on IMNM stock, click here.
More about Immunome
Immunome, Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, including antibody-drug conjugate therapies (ADCs), with its most advanced programs being varegacestat, a gamma secretase inhibitor in Phase 3 trials for desmoid tumors, IM-1021, a ROR1-targeted ADC in Phase 1 trials, and IM-3050, a FAP-targeted radioligand that recently received IND clearance.
Average Trading Volume: 1,095,026
Technical Sentiment Signal: Sell
Current Market Cap: $649.1M
See more data about IMNM stock on TipRanks’ Stock Analysis page.